Research programme: organophosphorus poisoning antidotes - Countervail Corporation/University of California at San Diego
Latest Information Update: 28 Jul 2016
At a glance
- Originator University of California, San Diego
- Developer Countervail Corporation
- Class Oximes
- Mechanism of Action Acetylcholinesterase modulators; Butyrylcholinesterase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Poisoning